Delivery Order SPE2DB20D3505-SPE2DB25FV0W6
- Not listed
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $20,048.58 to AmerisourceBergen Drug Corp for Lupron Depot 3.75 mg kits. This is a firm fixed-price, competitively awarded delivery order with an ultimate completion date of September 12, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026,...
- The Defense Logistics Agency (DLA) awarded a $17,899.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lupron Depot 3.75 mg kits, with an ultimate completion date of July 22, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,090.63 to AmerisourceBergen Drug Corp for Lupron Depot 3.75 mg kits, with a firm fixed price structure and no set-aside designation. The award was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Lupron Depot is a hormone treatment used in medical applications, and this delivery order represents a specific...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $17,212.04 by the Defense Logistics Agency (DLA) on August 8, 2025, for the supply of Lupron Depot 3.75 mg kits. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award. Performance will be fulfilled from the contractor's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 11, 2025. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $15,568.81 to AmerisourceBergen Drug Corp for the supply of Lupron Depot 11.25 mg 3-month kits. This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Lupron Depot is a hormone treatment medication used in medical applications, and this delivery order represents a specific procurement requirement under the...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,109,624 units of LUPRON DEPOT 3.75 MG KITS. The $2,004.11 contract has an ultimate completion date of March 29, 2024. Amerisourcebergen Drug Corp is the prime contractor and holds an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025, which...
- The Defense Logistics Agency awarded a delivery order valued at $13,483.53 to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits, with completion targeted for September 15, 2025. This competitively awarded, firm fixed-price delivery order is being performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting military and federal healthcare systems through...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,201.87 for Lupron Depot 11.25 mg 3-month kits, with an ultimate completion date of September 4, 2025. This is a firm fixed price delivery order under a non-set-aside competitive procurement. The contractor, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract...
- This is a $4,435.13 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for the supply of LUPRON DEPOT 11.25 MG 3MO KITS, a specialty medication product. The contract has an ultimate completion date of September 30, 2024 and does not utilize any set-aside designations. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to...
- The Defense Logistics Agency awarded a competitive delivery order valued at $9,449.34 to AmerisourceBergen Drug Corp for the supply of Lupron Depot 3.75 mg kits, with an ultimate completion date of April 23, 2025. This non-set-aside contract utilizes firm fixed price pricing and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's ongoing role as a critical pharmaceutical supplier to the federal...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FV0W6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,014.39 to AmerisourceBergen Drug Corp for the supply of Lupron Depot 3.75 mg kits. This competitively awarded, firm fixed-price contract has an ultimate completion date of July 31, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Lupron Depot is a leuprolide acetate-based pharmaceutical product used in hormonal therapies, and this order represents a single delivery transaction under the broader federal pharmaceutical supply framework. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying medications, vaccines, medical devices, and specialized healthcare commodities to military and veteran healthcare systems. The parent IDC enables the company to fulfill diverse pharmaceutical supply needs across multiple therapeutic domains in support of Defense Health Agency and other federal healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.0k | 7/30/25 |